舒肝宁注射液联合恩替卡韦治疗慢性肝炎肝纤维化临床研究  

Clinical study of Shuganning injection combined with Entecavir in the treatment of liver fibrosis in chronic hepatitis

作　　者：马侠槟 吴育龙 刘志成 Ma Xiabin;Wu Yulong;Liu Zhicheng(The Shantou Chaonan Minsheng Hospital,Shantou,Guangdong515100)

机构地区：[1]汕头潮南民生医院,广东汕头515100

出　　处：《基层医学论坛》2022年第13期1-3,7,共4页The Medical Forum

基　　金：汕头市科技计划医疗卫生类别项目(210521086490149)。

摘　　要：目的探讨舒肝宁注射液联合恩替卡韦治疗慢性肝炎肝纤维化的临床效果。方法选取68例汕头潮南民生医院2019年5月—2021年5月收治的慢性肝炎肝纤维化患者,采用随机数字表法进行分组,对照组接受恩替卡韦治疗,研究组接受舒肝宁注射液联合恩替卡韦治疗,对比2组疗效。结果研究组临床治疗总有效率(97.06%)较对照组(79.41%)高,差异有统计学意义(P<0.05)。2组患者治疗前肝功能以及肝纤维化指标对比无明显差异(P>0.05);治疗后,研究组患者的天冬氨酸转氨酶(AST)、总胆红素(TBiL)、丙氨酸转氨酶(ALT)均低于对照组;研究组层粘连蛋白(LN)、肝纤维化指标Ⅲ型前胶原(PCⅢ)、透明质酸(HA)均低于对照组(P<0.05)。头痛、发热、肌肉痛等不良反应发生率对比,研究组(2.94%)较对照组(11.76%)低,但差异无统计学意义(P>0.05)。结论舒肝宁注射液联合恩替卡韦治疗慢性肝炎肝纤维化,对改善患者的肝功能以及肺纤维化均有一定的疗效,且药物不良反应较小,治疗安全性较高,值得推广。Objective To explore the clinical study of Shuganning injection combined with entecavir in the treatment of liver fibrosis in chronic hepatitis.Methods Sixty-eight patients with chronic hepatitis and liver fibrosis in our hospital from May 2019 to May 2021 were selected and randomly divided into two groups.The control group was treated with entecavir,and the study group was treated with Shuganning injection combined with entecavir.Results The effective rate of clinical treatment in study group(97.06%)was higher than that in control group(79.41%),and the difference was statistically significant(P<0.05).There was no difference in liver function and liver fibrosis treatment between the two groups before treatment(P>0.05).After treatment,aspartate aminotransferase(AST),total bilirubin(TBIL)and alanine aminotransferase(ALT)in the study group were lower than those in the control group.The levels of laminin(LN),typeⅢprocollagen(PCⅢ)and hyaluronic acid(HA)in the study group were lower than those in the control group(P<0.05).Compared with the control group(11.76%),the incidence of headache,fever and muscle pain was lower in the study group(2.94%),with no significant difference(P>0.05).Conclusion Shuganning injection combined with entecavir can improve the liver function and pulmonary fibrosis of patients with chronic hepatitis,with less adverse drug reactions and higher treatment safety,which is worth popularizing.

关 键 词：慢性肝炎 肝纤维化 舒肝宁注射液 恩替卡韦 临床研究 

分 类 号：R256.4[医药卫生—中医内科学]